Pharmaceuticals

A new study argues state-imposed price caps on drugs fail to lower patient costs, instead threatening the supply chain for our most vulnerable citizens.

By selling its mass cytometry unit and securing a $30M payout, Standard BioTools is fortifying its balance sheet for a transformative merger with Treeline.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

NextPlat declares a strategic turnaround, but the real story is its complex model: blending high-margin healthcare with niche satellite tech. Can it deliver?

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.

With two blockbuster cancer drugs driving revenue, Syndax's upcoming Q2 report is a critical test of its path to profitability and ambitious pipeline.

A 76.5% approval rate seems acceptable, but new data reveals a fractured system where a patient's access to vital drugs is a lottery of delays and denials.

ADMA Biologics reported 20% growth, but a lawsuit alleges it was a sham built on channel stuffing and hidden deals. Here's what investors need to know.

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.

A new partnership in the booming peptide market signals a major shift. Novadose and Pure Pharmaceuticals are betting that future success won't just come from discovery, but from demonstrating unimpeachable quality and transparency.

A perfect storm of wonder drugs, AI-driven billing, and flawed policy is pushing employer health costs to a 15-year high, forcing a radical rethink of benefits.

As over 40% of Americans skip meds due to cost, a new report reveals the pivotal, money-saving role of health-system pharmacists. Here's how they help.

An upcoming summit for LGMD isn't just another conference. It's a key signal that patient advocacy, biotech innovation, and regulatory shifts are converging.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

With a new CMO and fresh funding, Spero Therapeutics is betting big on its immunology asset SP001. Can Dr. Zack guide it to success in a competitive field?